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Purpose: A 2011 survey on the practice of intensity-modulated 
radiotherapy (IMRT) in the treatment of vulvar carcinoma 
originally highlighted areas of controversy and subsequently lead 
to the establishment of consensus recommendations for 
contouring and treatment in vulvar carcinoma. The present study 
aims to outline changes in practice over the last five years. 
Methods and Materials: Radiation oncologists with an expertise 
in gynaecological malignancies from a multi-national consortium 
(North America, Australia and Europe) were asked to complete a 
web based survey in 2011, then in 2016. Questions covered a 
wide range of issues in regards to staging, planning and IMRT 
treatment of vulvar cancer. Pearson’s chi-squared test was used 
to compare the two surveys. 
Results: Thirty-five radiation oncologists completed the survey 
in 2011, 24 in 2016. Half of the respondents were from the USA. 
An increase in the use of IMRT was reported. In 2011, 29% have 
never used IMRT in the management of vulvar cancer, compared 
to 4% in 2016, and 23% have treated more than 10 patients with 
IMRT in 2011, compared to 75% in 2016 (p = 0.006). PET-CT was 
used for staging by 69% of respondents in 2011 as compared to 
88% in 2016 (p = 0.09). There was also an increase in the use of 
MRI for planning purposes (p = 0.018) and more physicians now 
report replanning during the course of treatment (74% versus 
25%; p = 0.001). More respondents now use a higher total dose (≥ 
66 Gy) to the primary lesion (55% versus 41%; p = 0.312) although 
it did not reach statistical significance. There remains 
controversy on the total dose to deliver to involved lymph nodes. 
Similarly, there remains considerable variation in clinical target 
volume (CTV) definitions for different clinical scenarios as well 
as dose constraints for organs at risk (OAR). There is a trend of 
an increasing bone marrow contouring by radiation oncologists 
(47% versus 29%; p = 0.19), but there is still considerable 
discrepancy in the pelvic bones selected to represent ‘bone 
marrow’. Weekly cisplatin at 40 mg/m2 remains the most 
commonly used concurrent chemotherapy regimen. 
Conclusions: The use of IMRT for vulvar cancer has increased 
over the past five years. CTV definition and OAR dose constraints 
remain the biggest areas of controversy, highlighting the need 
for new consensus recommendations. 
 
77 
A PRATICAL METRIC TO GUIDE PATIENTS SELECTION FOR BREATH-
HOLD RADIATION THERAPY (BH-RT) IN LEFT-SIDED BREAST 
CANCER 
Lucas C. Mendez1, Alexander V. Louie2, Carolina S. Moreno3, Eric 
Leung4, Roberto K. Sakuraba3, Juliana K. Helito3, Ana C. P. 
Rezende3, Ícaro T. Carvalho3, Eduardo Weltman3 
1University of São Paulo, São Paulo, Brazil 
2London Regional Cancer Program, London, ON 
3Hospital Israelita Albert Einstein, São Paulo, Brazil 
4Odette Cancer Centre, Toronto, ON 
 
Purpose: Patients with left-sided breast cancer receiving 
radiotherapy (RT) are at increased risk of cardiac toxicity. 
Anatomic features that predict which breast patients would 
benefit from BH-RT for cardiac-sparing have been proposed. The 
purpose of this study is to evaluate the performance of a new 
metric in comparison to existing predictors in determining the 
need for BH-RT. 
Methods and Materials: In this single institution study, 50 
randomly selected left-breast cancer patients treated with BH-
RT were evaluated. Free-breathing and breath-hold images are 
both acquired during planning and the former set were used in 
this analysis. Target volumes and organs at risk were contoured 
using RTOG and consensus-based atlases. Using a cut-off of > 10 
cc V50% or mean heart dose (MHD) ≥1.7 Gy as selection criteria 
for BH-RT, a study by Lee et al. previously described the 
parasagittal heart contact with the chest wall length 
(HeartContact) as the most accurate predictor of benefiting from 
BH-RT use. We evaluated the performance of HeartContact 
versus two new candidate variables, measured as the lateral 
length between the left sternal edge to the beginning of lung 
parenchyma at the 1) fourth (Arch4) and 2) fifth costal arch 
(Arch5) levels. These three independent variables were 
compared with mean heart dose (MHD), V50% heart volume and 
left anterior descending coronary (LAD) max dose. Recursive 
partioning analysis (RPA) was performed to define optimal cut-
points for independent variables. Sensitivity and specificity were 
calculated based on these parameters. Univariable regression 
analysis was used to identify significant predictors of breath hold 
end points. Statistical analyses were performed using SAS (v.9.4) 
with two-sided statistical testing at the 0.05 significance level. 
Results: The median patient age was 53 years and all underwent 
breast-conserving surgery. The MHD was 2.3 Gy (± 0.8) and mean 
V50% was 10.4 cc (± 9.7). RPA determined 73mm as the optimal 
cut-off for HeartContact, 13 mm for Arch4 and 60 mm for Arch5, 
respectively. When considering MHD ≥ 1.7 Gy to predict for BH-
RT, HeartContact sensitivity and specificity were 77% and 90%; 
with Arch4 yielding 80% and 90%, respectively. In the case of 
V50% ≥ 10 cc to predict for BH-RT, HeartContact sensitivity and 
specificity were 87% and 55%; Arch4 yielded values of 100% and 
63% respectively. Arch4 was more sensitive and specific in 
predicting BH-RT than Arch5. On univariable linear regression 
analysis, Heartcontact and Arch4 were found to be statistical 
significant predictors of MHD, V50% and LAD Max dose (p < 0.05). 
Receiver operating curves demonstrated that Arch4 was the most 
accurate predictor of high cardiac dose (MHD ≥ 1.7 Gy and V50% 
≥ 10 mL). 
Conclusions: Our proposed variable, Arch4 holds promise as a 
practical and accurate predictor of high heart dose and the need 
for BH-RT for left-sided breast cancer patients. An external 
validation study is planned to confirm the diagnostic 
performance of our novel variable. 
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Purpose: Despite possessing similar clinicopathological features, 
some PCa patients treated with RP are at high-risk of developing 
local and/or distant recurrence and dying of their cancer, 
whereas many others will have clinically insignificant disease and 
will not benefit from post-operative radiotherapy. A minimally 
invasive diagnostic assay is required to stratify these patients, 
monitor disease progression and response to treatment, 
ultimately improving patient care. Extracellular miRNAs 
embedded in circulating exosomes have sparked much interest 
as potential non-invasive biomarkers for PCa.  
Methods and Materials: Patients who had RP and were referred 
for post-operative radiotherapy were prospectively recruited 
and patient, tumour and treatment factors were abstracted and 
analyzed. Serum exosomes were isolated for extraction of 
miRNAs, and comparative profiling of miRNAs was performed 
